UY31919A - Derivados de dibenzotiazepinas y sus usos-424 - Google Patents

Derivados de dibenzotiazepinas y sus usos-424

Info

Publication number
UY31919A
UY31919A UY0001031919A UY31919A UY31919A UY 31919 A UY31919 A UY 31919A UY 0001031919 A UY0001031919 A UY 0001031919A UY 31919 A UY31919 A UY 31919A UY 31919 A UY31919 A UY 31919A
Authority
UY
Uruguay
Prior art keywords
dibenzotiazepinas
derivatives
disorder
compounds
schizophrenia
Prior art date
Application number
UY0001031919A
Other languages
English (en)
Inventor
Shenvi Ashokkumar
Phil D Edwards
Pierson Edward
Widzowski Dan
Brown Dean
Wesolowski Steven
Hulsizer James
Damewood James
James C Muir
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41431860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31919(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY31919A publication Critical patent/UY31919A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • C07D281/04Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16[b, f]-condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Compuestos de la siguiente fórmula: donde Z es como se describen en la memoria descriptiva, sales farmacéuticamente aceptables de los mismos, composiciones que los comprenden, y procedimientos para tratar el trastorno bipolar, un trastorno de ansiedad, un trastorno del humor o esquizofrenia, u otros trastornos psicóticos, con los referidos compuestos.
UY0001031919A 2008-06-20 2009-06-18 Derivados de dibenzotiazepinas y sus usos-424 UY31919A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7441708P 2008-06-20 2008-06-20

Publications (1)

Publication Number Publication Date
UY31919A true UY31919A (es) 2010-01-29

Family

ID=41431860

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001031919A UY31919A (es) 2008-06-20 2009-06-18 Derivados de dibenzotiazepinas y sus usos-424

Country Status (38)

Country Link
US (3) US20110160184A1 (es)
EP (1) EP2307389B1 (es)
JP (2) JP5468068B2 (es)
KR (1) KR20110019781A (es)
CN (1) CN102131791B (es)
AR (1) AR072200A1 (es)
AU (1) AU2009260905B2 (es)
BR (1) BRPI0914231A2 (es)
CA (1) CA2728675A1 (es)
CL (1) CL2010001471A1 (es)
CR (1) CR11860A (es)
CU (1) CU23884B1 (es)
CY (1) CY1113845T1 (es)
DK (1) DK2307389T3 (es)
DO (1) DOP2010000393A (es)
EA (1) EA201001889A1 (es)
EC (1) ECSP10010698A (es)
ES (1) ES2402084T3 (es)
HK (1) HK1156308A1 (es)
HN (1) HN2010002683A (es)
HR (1) HRP20130234T1 (es)
IL (2) IL210081A (es)
ME (1) ME01516B (es)
MX (1) MX2010014203A (es)
MY (1) MY157518A (es)
NI (1) NI201000224A (es)
NZ (1) NZ590616A (es)
PE (1) PE20110029A1 (es)
PL (1) PL2307389T3 (es)
PT (1) PT2307389E (es)
RS (1) RS52703B (es)
SI (1) SI2307389T1 (es)
SV (1) SV2010003769A (es)
TW (1) TWI488854B (es)
UA (1) UA105903C2 (es)
UY (1) UY31919A (es)
WO (1) WO2009154563A1 (es)
ZA (1) ZA201100488B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488854B (zh) * 2008-06-20 2015-06-21 Astrazeneca Ab 二苯并噻氮呯衍生物及其用途
US20160205082A1 (en) * 2013-08-12 2016-07-14 Graphite Software Corporation Secure authentication and switching to encrypted domains
CN103524455A (zh) * 2013-10-30 2014-01-22 苏州敬业医药化工有限公司 一种制备2-氯-二苯并[b,f][1,4]硫氮杂卓-11-[10H]酮的方法
WO2015074150A1 (en) 2013-11-21 2015-05-28 Graphite Software Corporation Managed domains for remote content and configuration control on mobile information devices
CN104447615A (zh) * 2014-02-28 2015-03-25 广东东阳光药业有限公司 喹硫平中间体的制备方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL294355A (es)
NL293201A (es)
DE1620703B2 (de) * 1960-08-16 1976-11-25 Ausscheidung aus: 12 80 879 Dr. A. Wander AG, Bern 11-basisch substituierte dibenzo eckige klammer auf b,f eckige klammer zu-eckige klammer auf 1,4 eckige klammer zu-thiazepine
CH422793A (de) 1961-07-20 1966-10-31 Wander Ag Dr A Verfahren zur Herstellung 11-basisch substituierter Dibenzo(b,f) (1,4)thiazepine
CH476753A (de) 1962-06-08 1969-08-15 Wander Ag Dr A Verfahren zur Herstellung von 11-basisch substituierter Dibenzo(b,f)(1,4)thiazepine
DE1620713A1 (de) * 1962-05-25 1970-07-02 Wander Ag Dr A Verfahren zur Herstellung von 11-basisch substituierter Dibenzo[b,f][1,4]thiazepine
NL140242B (nl) 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
BE632120A (es) 1963-05-09
US3683034A (en) 1963-09-27 1972-08-08 Upjohn Co Process for the preparation of substituted hydroquinones
US3908010A (en) 1967-03-22 1975-09-23 Wander Ag Dr A Basically substituted heterocycles as anti-emetics
US3884920A (en) 1967-07-14 1975-05-20 Sandoz Ag 11-Basically substituted dibenz {8 b,f{9 {0 {8 1,4{9 {0 oxazepines
US3412193A (en) 1965-12-13 1968-11-19 American Cyanamid Co 11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepines or thiazepines for controlling fertility
US3444169A (en) 1966-01-17 1969-05-13 American Cyanamid Co Process for 11 - aminodibenz(b,f)(1,4)oxazepines and analogous thiazepines
NL6715650A (es) 1966-12-16 1968-06-17
US3852446A (en) 1967-03-13 1974-12-03 Sandoz Ag Organic compounds in treatment of psychotic disturbances
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3758479A (en) 1967-03-22 1973-09-11 Sandoz Ag Nitro and sulphamoyl substituted dibenzodiazepines
CH569730A5 (es) * 1972-04-04 1975-11-28 Wander Ag Dr A
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
GB8705574D0 (en) 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
JPH04211071A (ja) * 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
JPH0565257A (ja) 1991-07-05 1993-03-19 Hokuriku Seiyaku Co Ltd 多環式化合物及びその用途
US5661184A (en) 1994-08-12 1997-08-26 Eli Lilly And Company Psychiatric agents
WO1996006098A1 (en) 1994-08-24 1996-02-29 Astra Aktiebolag Spiro-azabicyclic compounds useful in therapy
US5602121A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. Alkyl-substituted compounds having dopamine receptor affinity
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9702799D0 (sv) 1997-07-25 1997-07-25 Astra Ab New compounds
AU5489299A (en) 1998-08-18 2000-03-14 Sepracor, Inc. Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
JP2003505505A (ja) 1999-07-28 2003-02-12 オスヴァルト・ヴィス 運動時の酸素消費を低下するための製剤
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
SE0002729D0 (sv) 2000-07-20 2000-07-20 Astrazeneca Ab Novel compound form
AU2002249885A1 (en) 2000-11-17 2002-08-12 Adolor Corporation Delta agonist analgesics
IL139975A0 (en) 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
SI1395567T1 (sl) 2001-05-18 2009-04-30 Astrazeneca Ab 4-(fenil-piperazinil-metil)benzamidni derivati in njihova uporaba za zdravljenje bolečine, tesnobe ali gastrointestinalnih motenj
CA2455341A1 (en) 2001-06-01 2002-12-05 Astrazeneca Ab Novel ligand for nicotinic acetylcholine receptors useful in therapy
WO2003006026A1 (en) 2001-07-09 2003-01-23 Combinatorx, Incorporated Combinations for the treatment of inflammatory disorders
CN101445494A (zh) 2001-09-27 2009-06-03 特拉维夫大学拉莫特有限公司 共轭的精神抑制药及其用途
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
NZ535978A (en) 2002-04-18 2007-10-26 Astrazeneca Ab Novel spiroazabicyclic heterocyclic amines useful as nicotinic acetylcholine receptor agonists
NZ561993A (en) 2002-04-18 2008-09-26 Astrazeneca Ab Spiroazabicyclic heterocyclic amines as potent ligands for nicotinic acetylcholine receptors
BR0309343A (pt) 2002-04-18 2005-02-15 Astrazeneca Ab Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
SE0202465D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202598D0 (sv) 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
BR0314108A (pt) 2002-09-18 2006-04-25 Fmc Corp derivados tricìclios inseticidas
BR0317528A (pt) * 2002-12-20 2005-11-22 Basf Ag Uso dos compostos, métodos para o controle de insetos, aracnìdeos ou nematodos, e para a proteção de plantas em crescimento contra o ataque ou a infestação por insetos, aracnìdeos ou nematodos, compostos, e, composições
US20040224942A1 (en) 2003-01-23 2004-11-11 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
CA2516646A1 (en) 2003-02-22 2004-09-10 Teva Pharmaceutical Industries Ltd. Synthesis of quetiapine and pharmaceutically acceptable salts thereof
DE10310196A1 (de) 2003-03-06 2004-09-23 Rina-Netzwerk Rna Technologien Gmbh Verwendung eines trizyklischen Antidepressivums zur Förderung der Endozytose
JP2006523707A (ja) 2003-04-15 2006-10-19 アストラゼネカ アクツィエボラーグ 治療化合物
US20060217366A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating schizophrenia and other disorders
PL195728B1 (pl) 2003-07-18 2007-10-31 Helm Ag Sposób wytwarzania 11-(1-piperazynylo)dibenzo[b,f][1,4]tiazepiny
RU2394030C2 (ru) * 2003-12-22 2010-07-10 Акадиа Фармасьютикалз Инк. АМИНОЗАМЕЩЕННЫЕ АНАЛОГИ ДИАРИЛ [a,d] ЦИКЛОГЕПТЕНА В КАЧЕСТВЕ МУСКАРИНОВЫХ АГОНИСТОВ И СПОСОБЫ ЛЕЧЕНИЯ ПСИХОНЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ
PT1696931E (pt) 2003-12-22 2009-06-12 Acadia Pharm Inc Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas
US20060063754A1 (en) * 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder
KR20070106690A (ko) 2004-12-27 2007-11-05 아스트라제네카 아베 피라졸론 화합물 및 대사성 글루타메이트 수용체길항제로서 그들의 용도
JP2008526839A (ja) * 2005-01-07 2008-07-24 アストラゼネカ・アクチエボラーグ 11−ピペラジン−1−イルジベンゾ[b,f][1,4]チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用
US20060252744A1 (en) * 2005-04-04 2006-11-09 Burstein Ethan S Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
EP2099459A4 (en) 2006-12-20 2011-04-27 Astrazeneca Ab COMPOUNDS AND USES THEREOF
JP2010518104A (ja) 2007-02-09 2010-05-27 アストラゼネカ・アクチエボラーグ アザ−イソインドロンおよび代謝型グルタミン酸レセプター増強剤−613としてのそれらの使用
US7491871B2 (en) 2007-04-25 2009-02-17 Stine Seed Farm, Inc. Soybean cultivar S060299
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-842之用途
TWI488854B (zh) * 2008-06-20 2015-06-21 Astrazeneca Ab 二苯并噻氮呯衍生物及其用途

Also Published As

Publication number Publication date
JP2011524898A (ja) 2011-09-08
NZ590616A (en) 2012-09-28
CR11860A (es) 2011-02-25
CN102131791A (zh) 2011-07-20
IL210081A0 (en) 2011-02-28
HRP20130234T1 (hr) 2013-04-30
CY1113845T1 (el) 2016-07-27
AU2009260905B2 (en) 2012-08-23
HK1156308A1 (en) 2012-06-08
PT2307389E (pt) 2013-03-28
CN102131791B (zh) 2014-12-24
CU20100252A7 (es) 2011-11-15
RS52703B (en) 2013-08-30
JP5468068B2 (ja) 2014-04-09
ME01516B (me) 2014-04-20
CL2010001471A1 (es) 2011-05-06
HN2010002683A (es) 2013-01-15
EP2307389B1 (en) 2013-01-23
ZA201100488B (en) 2011-10-26
BRPI0914231A2 (pt) 2015-11-03
KR20110019781A (ko) 2011-02-28
JP2014098006A (ja) 2014-05-29
SI2307389T1 (sl) 2013-04-30
EP2307389A4 (en) 2012-04-11
TWI488854B (zh) 2015-06-21
UA105903C2 (uk) 2014-07-10
US20120202991A1 (en) 2012-08-09
ECSP10010698A (es) 2011-01-31
EP2307389A1 (en) 2011-04-13
IL210081A (en) 2013-12-31
US20110160184A1 (en) 2011-06-30
IL229560A (en) 2015-07-30
PE20110029A1 (es) 2011-02-11
US8653257B2 (en) 2014-02-18
MX2010014203A (es) 2011-02-22
AU2009260905A1 (en) 2009-12-23
US8158618B2 (en) 2012-04-17
NI201000224A (es) 2012-03-19
MY157518A (en) 2016-06-15
ES2402084T3 (es) 2013-04-26
CA2728675A1 (en) 2009-12-23
IL229560A0 (en) 2014-01-30
TW201002702A (en) 2010-01-16
DOP2010000393A (es) 2011-01-31
SV2010003769A (es) 2011-05-20
WO2009154563A1 (en) 2009-12-23
EA201001889A1 (ru) 2011-08-30
US20090318415A1 (en) 2009-12-24
AR072200A1 (es) 2010-08-11
DK2307389T3 (da) 2013-04-02
CU23884B1 (es) 2013-04-19
PL2307389T3 (pl) 2013-05-31

Similar Documents

Publication Publication Date Title
CO6612267A2 (es) Nuevos derivados de 1,1 dióxido- 5 fenil- 2,3,4-5tetrahidro- 1,4-benzotiazepina y composiciones farmaceúticas que los comprenden
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
CO6460766A2 (es) Compuestos de haloalquil heteroaril benzamida
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
SV2010003642A (es) Compuestos
NI201100166A (es) Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa
GT201400031A (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
DOP2012000151A (es) Nuevos compuestos triciclicos
CL2013003731A1 (es) Compuestos derivados de carboxamida; composición farmacéutica que los comprende, y su uso como inhibidores de la fosfodiesterasa tipo 10a (pde10a) para el tratamiento de trastornos del snc, esquizofrenia, disfunción cognitiva relacionada con la esquizofrenia, trastornos bipolares, depresión, disfunción cognitiva, alteraciones cognitivas, trastornos del comportamiento asociados a la enfermedad de alzheimer, obesidad, enfermedad de huntington y ansiedad.
NI201500134A (es) Derivados de 2-((4-amino-3-(3-flúor-5-hidroxifenil)-1h-pirazolo[3,4-d]pirimidin-1-il) metil)-3-(2-(trifluorometil)bencil)quinazolina-4(3h)-ona y su uso como inhibidores de fosfoinositida 3-quinasas
CO6351780A2 (es) Nuevas benzamidas, su preparaccion y su uso como medicamentos
UY32296A (es) Nuevos compuestos
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
UY31159A1 (es) Derivados de quinolina, métodos para su fabricación, composiciones farmacéuticas de los mismos y usos de los mismos
AR079945A1 (es) Derivados de pirazina como inhibidores de glucogeno sintasa quinasa 3 (gsk3)
CO2018007278A2 (es) Derivados de ácido aminobenzoico metaazacíclico como antagonistas de la integrina pan
CU24052B1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos
UY31919A (es) Derivados de dibenzotiazepinas y sus usos-424
CO2017003305A2 (es) Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa
CR20150148A (es) Azaindolinas
NI201100035A (es) Agentes antifúngicos.
CL2012003539A1 (es) Compuestos derivados de alquil-piperazino-fenil 4(3h)ona; composicion farmaceutica y su uso para el tratamiento de los trastornos asociados a los receptores serotoninergicos 5-ht1a y 5-ht2a, tales como depresion, ansiedad, y trastornos del sueño.
UY32843A (es) Octasacáridos n-acilos activadores de los receptores de los fgf, su preparación y su aplicación en terapéutica

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181106